173 related articles for article (PubMed ID: 35696800)
1. Tabersonine attenuates Angiotensin II-induced cardiac remodeling and dysfunction through targeting TAK1 and inhibiting TAK1-mediated cardiac inflammation.
Dai C; Luo W; Chen Y; Shen S; Wang Z; Chen R; Wang J; Chattipakorn N; Huang W; Liang G
Phytomedicine; 2022 Aug; 103():154238. PubMed ID: 35696800
[TBL] [Abstract][Full Text] [Related]
2. Sclareol attenuates angiotensin II-induced cardiac remodeling and inflammation via inhibiting MAPK signaling.
Yang N; Zou C; Luo W; Xu D; Wang M; Wang Y; Wu G; Shan P; Liang G
Phytother Res; 2023 Feb; 37(2):578-591. PubMed ID: 36178264
[TBL] [Abstract][Full Text] [Related]
3. Sialyltransferase7A promotes angiotensin II-induced cardiomyocyte hypertrophy via HIF-1α-TAK1 signalling pathway.
Yan X; Zhao R; Feng X; Mu J; Li Y; Chen Y; Li C; Yao Q; Cai L; Jin L; Han C; Zhang D
Cardiovasc Res; 2020 Jan; 116(1):114-126. PubMed ID: 30854566
[TBL] [Abstract][Full Text] [Related]
4. Diacerein alleviates Ang II-induced cardiac inflammation and remodeling by inhibiting the MAPKs/c-Myc pathway.
Wang M; Luo W; Yu T; Liang S; Zou C; Sun J; Li G; Liang G
Phytomedicine; 2022 Nov; 106():154387. PubMed ID: 36027716
[TBL] [Abstract][Full Text] [Related]
5. Tabersonine alleviates obesity-induced cardiomyopathy by binding to Transforming growth factor activated kinase 1 (TAK1) and inhibiting TAK1-mediated inflammation.
Chen Y; Lin W; Chen P; Ye B; Luo W; Wang X; Huang W; Wu G; Liang G
Phytother Res; 2023 Mar; 37(3):860-871. PubMed ID: 36420902
[TBL] [Abstract][Full Text] [Related]
6. Leonurine attenuates angiotensin II-induced cardiac injury and dysfunction via inhibiting MAPK and NF-κB pathway.
Shen S; Wu G; Luo W; Li W; Li X; Dai C; Huang W; Liang G
Phytomedicine; 2023 Jan; 108():154519. PubMed ID: 36332391
[TBL] [Abstract][Full Text] [Related]
7. Lycorine inhibits Ang II-induced heart remodeling and inflammation by suppressing the PI3K-AKT/NF-κB pathway.
Tuo P; Zhao R; Li N; Yan S; Yang G; Wang C; Sun J; Sun H; Wang M
Phytomedicine; 2024 Jun; 128():155464. PubMed ID: 38484625
[TBL] [Abstract][Full Text] [Related]
8. TBC1D25 Regulates Cardiac Remodeling Through TAK1 Signaling Pathway.
Guo S; Liu Y; Gao L; Xiao F; Shen J; Xing S; Yang F; Zhang W; Shi Q; Li Y; Zhao L
Int J Biol Sci; 2020; 16(8):1335-1348. PubMed ID: 32210723
[TBL] [Abstract][Full Text] [Related]
9. Corynoline protects ang II-induced hypertensive heart failure by increasing PPARα and Inhibiting NF-κB pathway.
Wang M; Luo W; Yu T; Liang S; Sun J; Zhang Y; Han X; Long X; Liang G; Li G
Biomed Pharmacother; 2022 Jun; 150():113075. PubMed ID: 35658238
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin-specific protease 19 blunts pathological cardiac hypertrophy via inhibition of the TAK1-dependent pathway.
Miao R; Lu Y; He X; Liu X; Chen Z; Wang J
J Cell Mol Med; 2020 Sep; 24(18):10946-10957. PubMed ID: 32798288
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol prevents Ang II-induced cardiac hypertrophy by inhibition of NF-κB signaling.
Ma E; Wu C; Chen J; Wo D; Ren DN; Yan H; Peng L; Zhu W
Biomed Pharmacother; 2023 Sep; 165():115275. PubMed ID: 37541173
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II-induced cardiomyocyte hypertrophy in vitro is TAK1-dependent and Smad2/3-independent.
Watkins SJ; Borthwick GM; Oakenfull R; Robson A; Arthur HM
Hypertens Res; 2012 Apr; 35(4):393-8. PubMed ID: 22072105
[TBL] [Abstract][Full Text] [Related]
13. SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy.
Tang X; Chen XF; Wang NY; Wang XM; Liang ST; Zheng W; Lu YB; Zhao X; Hao DL; Zhang ZQ; Zou MH; Liu DP; Chen HZ
Circulation; 2017 Nov; 136(21):2051-2067. PubMed ID: 28947430
[TBL] [Abstract][Full Text] [Related]
14. Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway.
Li CY; Zhou Q; Yang LC; Chen YH; Hou JW; Guo K; Wang YP; Li YG
Basic Res Cardiol; 2016 Mar; 111(2):19. PubMed ID: 26891723
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling.
Izumiya Y; Kim S; Izumi Y; Yoshida K; Yoshiyama M; Matsuzawa A; Ichijo H; Iwao H
Circ Res; 2003 Oct; 93(9):874-83. PubMed ID: 14551246
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside Rg5 alleviates Ang II-induced cardiac inflammation and remodeling by inhibiting the JNK/AP-1 pathway.
Yu T; Xu X; Wei J; Xu J; Luo W; Li A; Liang G; Wang M
Int Immunopharmacol; 2023 Jul; 120():110408. PubMed ID: 37276830
[TBL] [Abstract][Full Text] [Related]
17. Vinpocetine Attenuates Pathological Cardiac Remodeling by Inhibiting Cardiac Hypertrophy and Fibrosis.
Wu MP; Zhang YS; Xu X; Zhou Q; Li JD; Yan C
Cardiovasc Drugs Ther; 2017 Apr; 31(2):157-166. PubMed ID: 28321644
[TBL] [Abstract][Full Text] [Related]
18. Salidroside ameliorates pathological cardiac hypertrophy via TLR4-TAK1-dependent signaling.
Guo Z; Liu FY; Yang D; Wang MY; Li CF; Tang N; Ma SQ; An P; Yang Z; Tang QZ
Phytother Res; 2023 May; 37(5):1839-1849. PubMed ID: 36512326
[TBL] [Abstract][Full Text] [Related]
19. Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway.
Liao HH; Zhang N; Meng YY; Feng H; Yang JJ; Li WJ; Chen S; Wu HM; Deng W; Tang QZ
Oxid Med Cell Longev; 2019; 2019():6304058. PubMed ID: 31885808
[TBL] [Abstract][Full Text] [Related]
20. Gramine protects against pressure overload-induced pathological cardiac hypertrophy through Runx1-TGFBR1 signaling.
Xu L; Su Y; Yang X; Bai X; Wang Y; Zhuo C; Meng Z
Phytomedicine; 2023 Jun; 114():154779. PubMed ID: 37023527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
